GlassScriptPhysician profile
Lorraine M Childs
NPI 1558498139
$2,438.90
in general payments reported to CMS, 2019-2025
26 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $136 · 2023: $47.47 · 2024: $1,030 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $453.09 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $294.07 | 2022-2025 | Verquvo, Capvaxive |
| Amgen INC. | $248.12 | 2024-2025 | Repatha, Repatha |
| Bridgebio Pharma, INC. | $204.48 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $144.36 | 2021-2025 | |
| United Therapeutics Corporation | $102.99 | 2021-2024 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $95.64 | 2022-2025 | Farxiga, Wainua |
| Pfizer INC. | $94.74 | 2024-2025 | |
| Esperion Therapeutics, INC. | $94.55 | 2024-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $93.96 | 2024 | |
| Janssen Pharmaceuticals, INC | $90.04 | 2022-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $86.08 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.45 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $55.22 | 2021-2025 | Shingrix, Arexvy |
| Boston Scientific Corporation | $42.34 | 2025 | Watchman Flx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $41.32 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $38.72 | 2024-2025 | Ozempic, Wegovy |
| Inspire Medical Systems, INC. | $37.20 | 2025 | Inspire |
| Jazz Pharmaceuticals INC. | $33.09 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $25.95 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $22.09 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $21.82 | 2025 | Eliquis |
| Biogen, INC. | $20.18 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.35 | 2021 | |
| Cvrx, INC. | $13.16 | 2025 | Barostim Neo System |
| Bsn Medical INC | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Childs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.